Associate Dean for Clinical Research Strategy, Rudolf L. Baer Professor of Dermatology, Professor of Departments of Medicine (Oncology) and Urology, Director of the NYU Melanoma SPORE, Director of the Interdisciplinary Melanoma Cooperative Group (IMCG) New York University (NYU) Grossman School of Medicine
BIOGRAPHY
Speaker
Event Date & Time
Date: October 30, 2024
Time: 8:00 AM (PT), 11:00 AM (ET), 4:00 PM (CET)
Abstract
Predicting patient outcomes in cancer treatment is key to creating personalized and effective therapeutic plans. Join Dr. Osman in this engaging webinar as she delves into the cutting-edge world of autoantibody profiling to uncover predictive signatures of response and toxicity of immune checkpoint inhibitors (ICIs) in melanoma patients.
Learning Objectives
- Navigate Cancer Treatment Challenges: Understand the complexities of immune-related adverse events (irAEs) caused by ICIs
- Discover Dr. Osman's Approach: Learn why Dr. Osman chose to focus on profiling autoantibodies as a tool to identify biomarkers that predict treatment outcomes.
- Unveil the Biomarker Discovery Process: Explore how these autoantibody biomarkers were identified and validated, paving the way for personalized cancer therapies.
- See the Promising Results: Gain an insider's view of the groundbreaking results that could revolutionize treatment for melanoma and potentially other cancers.
- Look Ahead: Find out what the next steps are for advancing this innovative research.
While the presentation centers on cancer autoantibody biomarkers, it offers valuable insights for anyone interested in the transformative potential of antibody profiling in the broader field of medical research.
This webinar will be available for unlimited on-demand viewing after June 3, 2025.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.